Global Epigenetics Market Expected To Generate a Revenue Of Over $3 Billion By 2028

The global epigenetics market was valued at around $ 0.9 billion and is expected to grow at a CAGR of 14.65% by 2028 and generate a revenue of over $3 billion during the forecast period.

Epigenetics refers to the study of changes in the heritable phenotype without any alterations in the DNA sequence. The term may also encompass changes made in the genome but does not include any modifications in nucleotide sequence and examples of such mechanisms are histone modification and DNA methylation. The control of gene expression is through the repressor proteins action that is attached to the silencer area of the DNA, these changes may either last through the cell’s life even during cell division or may last for multiple generations without impacting the original DNA sequence.

Since epigenetic enzymes can reverse the epigenetic mutation incorporation, they have become a favorite of researchers for cancer treatments. As of 2022, 7 epigenetics drugs have been approved by the U.S. FDA that are used in the treatment of 5 histone inhibitors and 2 methyltransferase inhibitors. The indicators for the approval of epigenetic drugs are hematological malignancies and none of them are for solid tumors, however, research is being conducted for the same. Epigenetic drugs are expected to show the best results when used in combination therapy along with radiation and chemotherapy.

Covid-19 aided the global market growth majorly due to the extensive research conducted worldwide to understand the correlation between the virus and epigenetic mutations. The increased number of medical cases during Covid-19 also assisted in the rise in interest of different diagnostic clinics towards epigenetics.

The global epigenetics market growth is expected to spur due to the rising number of applications of epigenetics in the treatment of cancer and other disorders. Since epigenetics has proven to be highly efficient in treating certain types of cancer, it is being thoroughly researched by multiple research institutes with the intention to develop necessary drugs and vaccines for disorders that do not have any proper treatments assigned to them. Organizations like the National Cancer Institute, Human Epigenome Consortium, and National Institute of Health have been pushing for higher investment in epigenetics not just for research purposes but for commercialization as well which is expected to aid global market expansion in the coming years. A lot of key players are now entering into strategic mergers and acquisitions in the epigenetics industry either to increase their global presence or to boost the small-scale manufacturers with their production or innovation thus meeting the globally rising demand along with the addition of newer and more advanced tools that can be used in epigenetics and it may also propel the global market growth.

The standardization concerns related to epigenetics may restrict the global market growth. The adoption of advanced technology is expected to provide global market growth opportunities.

However, a lack of skilled professionals may challenge the global market expansion.

The global epigenetics market is segmented by end-user, product, application, and region.

By end-user, the global market segments are pharmaceutical & biotechnological companies, academic & research institutes, and contract research organizations. The global market was dominated by the pharmaceutical & biotechnological companies in 2021 and may follow the same trend during the projection period owing to increased R&D activities in genetics and towards the development of disease-specific treatments coupled with analysis of drug resistance in microorganisms, and molecular studies of cancer and other disorders.

By product, the global market is segmented into reagents, kits, instruments, and enzymes. Reagents like histone & DNA modified are most frequently used whereas PCR, antibodies, and electrophoresis reagents are most commonly utilized epigenetic reagents. PyroMarket Q24 uses pyrosequencing chemistry and is able to deliver the most efficient form of detection in real-time.

By product, the global market is divided into non-oncology and oncology. In 2021, the highest revenue was generated through applications in the oncology segment because of an increased number of cancer-related cases. Epimutations play a pivot role in cancer etiology and are being heavily researched as of current times.

North America is expected to dominate the global epigenetics market during the forecast period because of the rising number of cancer patients in the region along with the advanced economic state of countries like the USA and Canada where the income capability of the population is relatively higher and they can afford the cost of cancer treatments. The excellent medical reimbursement policies of the governments are expected to encourage the population towards enrolling in cancer treatment which will subsequently aid regional growth.

Asia-Pacific is anticipated to grow significantly as well owing to the regions like India and China witnessing high medical tourism because of the availability of relatively lower costing cancer treatments. The regional growth may also be attributed to the rising strategic collaborations between international organizations and domestic players to expand their consumer databases.

The global epigenetics market is led by players like Hologic Inc., Agilent Technologies, Inc., Merck Millipore, PerkinElmer, Inc., QIAGEN N.V., Illumina Inc., Thermo Fisher Scientific Inc., Abcam Plc., Zymo Research, and Active Motif, Inc.

Recent Development:

• In December 2021, Lonza and Agilent Technologies formed a partnership. Lonza is a leading manufacturer of cell and gene therapy. The partnership aims to bring drastic changes in the way customized cell therapies are created and used.
• In June 2021, Microba Life Sciences and Illumina entered a partnership with the intention to aid researchers with their inventions. The partnership will allow for Microba's extremely high-quality gut microbiome analysis platform and Illumina’s NGS tools to be able to create accurate metagenomic data.

Browse the full “Global Epigenetics Market By End User (Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, and Contract Research Organizations), By Product (Reagents, Kits, Instruments, and Enzymes), By Application (Non-Oncology and Oncology), and By Region - Global and Regional Industry Overview, Market Intelligence, Comprehensive Analysis, Historical Data, and Forecasts 2022 – 2028.” Report at https://www.zionmarketresearch.com/report/epigenetics-market

Global epigenetics market is segmented as follows:

By end-user:

•  Pharmaceutical & Biotechnology Companies
•  Academic & Research Institutes
•  Contract Research Organizations

By Product

•  Reagents
•  Kits
•  Instruments
•  Enzymes

By Application

•  Non-Oncology
•  Oncology

By Region

• North America
  • The U.S.
  • Canada
• Europe
  • France
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa

About Us:

Zion Market Research is an obligated company. We create futuristic, cutting-edge, informative reports ranging from industry reports, the company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client’s needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us—after all—if you do well, a little of the light shines on us.

Contact Us:

Zion Market Research
244 Fifth Avenue, Suite N202
New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll-Free No.1-855-465-4651
Email: sales@zionmarketresearch.com
Website: https://www.zionmarketresearch.com